The earnings call was largely positive, showcasing strong financial performance, significant revenue growth, and successful product expansions. However, the increase in operational expenses and challenges in early cancer detection present areas to watch.

Company Guidance

During Natera's 2025 Third Quarter Financial Results Conference Call, the company raised its full-year revenue guidance significantly, expecting revenues between $2.18 billion and $2.26 billion, which is a $160 million increase at the midpoint. This revision was driven by a robust 35% year-on-year revenue growth, totaling $592 million for the quarter, and record performance in their Signatera product, with 202,000 clinical MRD tests processed, reflecting a growth of 21,500 units compared to the previous quarter. Natera also increased its gross margin guidance to 62% to 64%, supported by a 64.9% gross margin in Q3, a notable improvement from prior quarters. Operationally, the company anticipates modestly higher operating expenses due to one-time costs totaling approximately $60 million, alongside an uptick in R&D to support expanded MolDx coverage. Natera also raised its free cash flow generation guidance, now expecting to generate roughly $100 million in cash for the full year.

Record Revenue Growth

Natera generated $592 million in revenue, up 35% over Q3 of the previous year, driven by strong growth across the product portfolio and another record for Signatera growth.

Increase in Financial Guidance

The company significantly increased the 2025 financial guidance, raising revenue guidance by $160 million at the midpoint, expecting revenues in the range of $2.18 billion to $2.26 billion.

Strong Gross Margin Performance

Gross margin improved to 64.9%, nearly 1.5 percentage points higher than the previous quarter, driven by better ASPs and COGS efficiencies.

Signatera Growth and Market Expansion

Processed 202,000 clinical MRD tests, with a record of 21,500 additional units, representing 56% year-on-year growth. The company plans to submit 7 new MolDx submissions by year-end, potentially adding $250 million to $300 million in gross profit.

Fetal Focus Product Expansion

Launched a new single-gene NIPT for inherited conditions with plans to expand the panel to cover over 20 genes, receiving positive initial feedback.

Strong Cash Flow and Balance Sheet

The company expects to generate roughly $100 million in free cash flow for the full year, with no permanent debt and a cash balance above $1 billion.

Natera (NTRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NTRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	-0.50 / -	-0.41	―	―	―
Nov 06, 2025	2025 (Q3)	-0.39 / -0.64	-0.26	-146.15% (-0.38)
Aug 07, 2025	2025 (Q2)	-0.61 / -0.74	-0.3	-146.67% (-0.44)
May 08, 2025	2025 (Q1)	-0.64 / -0.50	-0.56	10.71% (+0.06)
Feb 27, 2025	2024 (Q4)	-0.38 / -0.41	-0.65	36.92% (+0.24)
Nov 12, 2024	2024 (Q3)	-0.57 / -0.26	-0.95	72.63% (+0.69)
Aug 08, 2024	2024 (Q2)	-0.69 / -0.30	-0.97	69.07% (+0.67)
May 09, 2024	2024 (Q1)	-0.70 / -0.56	-1.23	54.47% (+0.67)
Feb 28, 2024	2023 (Q4)	-0.77 / -0.65	-1.37	52.55% (+0.72)
Nov 08, 2023	2023 (Q3)	-0.96 / -0.95	-1.25	24.00% (+0.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NTRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$198.48	$199.57	+0.55%
Aug 07, 2025	$141.08	$151.95	+7.70%
May 08, 2025	$162.57	$151.95	-6.53%
Feb 27, 2025	$156.61	$155.59	-0.65%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Natera Inc. (NTRA) report earnings?

Natera Inc. (NTRA) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).

What is Natera Inc. (NTRA) earnings time?

Natera Inc. (NTRA) earnings time is at Mar 04, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NTRA EPS forecast?

NTRA EPS forecast for the fiscal quarter 2025 (Q4) is -0.5.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing